



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Barbara K. Finck

Serial No.: 09/373,828

Filing Date: August 13, 1999

For: SOLUBLE TUMOR NECROSIS FACTOR RECEPTOR  
TREATMENT OF PSORIASIS AND PSORIATIC ARTHRITIS

BOX NON-FEE  
Assistant Commissioner for Patents  
Washington, D.C. 20231

Docket No.: 2945

Group Art Unit: 1617

Examiner: to be assigned

RECEIVED

NOV 29 1999

INFORMATION DISCLOSURE STATEMENT TECH CENTER 1600/2900

Dear Sir:

Pursuant to the duty of disclosure as set forth in 37 C.F.R. §1.56, §1.97 and §1.98, Applicant hereby discloses publications known to her which may be material to the patentability of this invention. The publications are listed on the attached Form PTO-1449, and a copies are enclosed. Kindly acknowledge receipt of this Statement and make the cited references of record in the subject application.

Submission of these publications does not constitute an admission that any are "prior art" under 35 U.S.C. §102 or §103, and Applicant specifically reserves the right to antedate any such material as by a showing under 37 C.F.R. §1.131 or other method. Applicant submits that the claims of the above-captioned application are directed to subject matter that is patentably distinct from the disclosures of the above-cited references.

To Applicant's knowledge, no office action on the merits has been mailed in the subject application. Thus, no fee is due for the filing of this information disclosure statement.

Respectfully submitted,

*Diana K. Sheiness*

Diana K. Sheiness  
Registration No. 35,356

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
Telephone (206) 587-0430

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: BOX NON-FEE, Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date: November 22, 1999

Signed

*Kathleen F. Prindle*  
Kathleen F. Prindle